On December 1st, Shao Yuanchang, deputy director of Zhejiang Provincial Pharmaceutical Administration, and his delegation visited our company to carry out the work of "three services" and promote the policy of "one enterprise and one policy". Ye Xingfu, member of the Party Committee and deputy director of Taizhou Market Supervision Administration, Xu Yueping, deputy head of Xianju County people's Government and other leaders of relevant departments of the city and county accompanied the investigation.

 

At the meeting, Woo Kam-Sang, chairman of woo Kam-Sang, briefed the leaders on the basic situation, development process, product layout and r&d registration of woo Kam-sang. He also briefed them on the preparation products of Woo Kam-Sang This year. He said that iopatol injection, Iohexol injection and ioxanol injection were the first products to be registered in the new 4 categories (regarded as "drug consistency evaluation"), which filled the gap in the preparation part of The Pharmaceutical industry chain of Staili, and enabled the company to successfully complete the industrial transformation and upgrading from bulk drugs to preparations. The pharmaceutical products of the company should compete with the original research units abroad, effectively adjust the drug price, so as to make the domestic people respect the disease, and make contributions to the cause of the people's health.

 

Having listened to Woo Kam-Woo, he and his team gave the company a lot of credit for its r&d, registration and so on. Shao yuanchang pointed out that The company has achieved good results in drug r&d and registration, which is inseparable from the company's efforts. The state has formulated a series of laws and regulations as well as a series of policies on drug management. Pharmaceutical enterprises must abide by these laws and regulations and make good use of these policies. We believe that Stellite will make better achievements in the future. We will also support the development of the company and implement the "three services" work to achieve accurate service.

 

At the meeting, the provincial Food and Drug Administration and other municipal and county leaders also communicated with the company's R&D and registration departments on matters related to drug evaluation and registration.